An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

NCT02917993 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Itacitinib
DRUG: Osimertinib

Sponsor

Incyte Corporation

Collaborators

[object Object]